Education
About Us
Working with TipRanks
Follow Us
Ribomic, Inc. (JP:4591)
:4591
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥141.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥5.38B
Enterprise Value¥2.59B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding54,332,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.30
Price to Sales (P/S)1880.02
P/FCF Ratio-3.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially lowers refinancing and interest risk, preserving strategic optionality over months. This durable strength gives management flexibility to raise capital on better terms, delay costly refinancing, or prioritize R&D/clinical spend without immediate debt servicing pressure.
Positive Gross Profit Where Revenue ExistsConsistent positive gross margins when revenue occurs indicate viable unit economics for products/services. If management can scale sales or stabilize revenue, margins could support operating leverage and long-term profitability once fixed costs and R&D intensity are reduced or matched by recurring revenue.
Cash Burn Roughly Tracks Accounting LossesCash outflows aligning with reported losses imply limited hidden cash leakage and more predictable funding needs. This transparency aids planning and indicates that reducing reported losses through cost control or revenue growth should translate directly into cash conservation over the next several quarters.
Bears Say
Minimal, Volatile RevenueVery low and inconsistent revenue prevents coverage of fixed costs and blocks scale economics. Structural reliance on irregular receipts undermines reproducible growth, forcing continued reliance on external funding and making sustainable margin expansion unlikely without clear commercialization progress.
Large Persistent Cash BurnSustained billion-yen cash outflows erode reserves and create recurring financing needs. Persistently negative operating and free cash flow constrains strategic choices, risks dilution from future capital raises, and threatens continuity unless revenue materially improves or expense structure is permanently reduced.
Declining Equity / Capital ErosionHalving of shareholders' equity over several years signals accumulation of losses and possible dilution, weakening the balance sheet buffer. Reduced equity lowers resilience to setbacks and increases dependence on external funding, limiting the firm’s ability to invest or absorb operational shocks.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥72.00 and its highest was ¥141.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥5.38B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is May 19, 2026 which is in 56 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Feb 12, 2026. The company reported -¥4.67 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.67.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 54,332,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Linical Co., Ltd.
―
CanBas Co., Ltd.
―
Takara Bio Inc.
―